investors

Utilizing its proprietary LNA Drug Platform and Drug Discovery Engine capabilities, Santaris Pharma A/S maximizes value by leveraging partnerships for broader pipeline and funding while building and maintaining a focused internal pipeline. Santaris Pharma A/S is rapidly becoming the partner-of-choice for pharmaceutical companies interested in commercializing RNA-targeted therapies.

The Denmark and U.S. offices of Santaris Pharma A/S maximize the company’s ability to access top talent and research, clinical and business opportunities in both Europe and the U.S.  Santaris Pharma A/S continues to provide significant value to its stakeholders while bringing RNA medicines one step closer to reality, today.

Annual Report

Santaris Pharma A/S Annual Report 2011
Santaris Pharma A/S Annual Report 2010
Santaris Pharma A/S Annual Report 2009
Santaris Pharma A/S Annual Report 2008
Santaris Pharma A/S Annual Report 2007
Santaris Pharma A/S Annual Report 2006
Santaris Pharma A/S Annual Report 2005
Santaris Pharma A/S Annual Report 2004
Santaris Pharma A/S Annual Report 2003

Quarterly Report

Santaris Pharma A/S Interim Report 1 January to 30 September 2011
Santaris Pharma A/S Interim Report 1 January to 30 June 2011
Santaris Pharma A/S Interim Report 1 January to 31 March 2011
Santaris Pharma A/S Interim Report 1 January to 30 September 2010
Santaris Pharma A/S Interim Report 1 January to 30 June 2010
Santaris Pharma A/S Interim Report 1 January to 31 March 2010
Santaris Pharma A/S Interim Report 1 January to 30 September 2009
Santaris Pharma A/S Interim Report 1 January to 30 June 2009
Santaris Pharma A/S Interim Report 1 January to 31 March 2009
Santaris Pharma A/S Interim Report 1 January to 30 June 2008
Santaris Pharma A/S Interim Report 1 January to 30 September 2008